biotech · Dystrophic Epidermolysis Bullosa · Autosomal Recessive Ichthyosis · KRYS
Krystal Biotech Netherlands
Krystal Biotech Netherlands B.V.
Krystal Biotech Netherlands is a biotech organization headquartered in Pittsburgh, USA. It trades on NYSE under ticker KRYS. Primary therapeutic focus areas include Dystrophic Epidermolysis Bullosa, Autosomal Recessive I
2100 Wharton Street, Suite 701, Pittsburgh, PA 15203, US HQ
2016 Founded
306 Employees
Public company Type
KRYS · NYSE Ticker
Company details
- Status
- Public
- HQ
- 2100 Wharton Street, Suite 701, Pittsburgh, PA 15203, US
- Founded
- 2016
- Employees
- 306
- Programs
- 14
- Drugs
- 7
- Patents
- 14
Open Label Topical Beremagene Geperpavec (B-VEC)
Phase 3 · mab · Dystrophic Epidermolysis Bullosa
Open Label Topical Beremagene Geperpavec (B-VEC) for Dystrophic Epidermolysis Bullosa is a Phase 3 program (mab) at Krystal Biotech Netherlands B.V. with 1 ClinicalTrials.gov record(s).
Internal code B-VEC-EX-02
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Krystal Biotech Netherlands B.V.
- Phase
- Phase 3
- Modality
- mab
- Indication
- Dystrophic Epidermolysis Bullosa
- Status
- completed
- Trials
- 1